
Bristol Myers Squibb outgrows Novo Nordisk in 2027 with rising revenue and net income despite pricing pressures.
Bristol Myers Squibb is expected to grow revenue by 3% and net income by over 40% in 2027, benefiting from new growth brands and a strong pipeline despite challenges like pricing pressures and patent expirations. Novo Nordisk, while dominant in obesi...





